Ipsen Positive On Palovarotene Despite Troubled Past
Filings For FOP In Early 2021
Executive Summary
Despite concerns over toxicity due to early growth plate closure in skeletally immature patients, Ipsen's CEO David Loew is confident that palovarotene will get through regulatory review for fibrodysplasia ossificans progressive.
You may also be interested in...
Ipsen’s Palovarotene Ultra-Rare Bone Disorder Drug Faces Hurdles At US FDA Adcomm
Agency questions whether post hoc analyses and use of natural history subjects as an external control group in a Phase III study support effectiveness of palovarotene; cites apparent increased incidence of flare-up events as a key safety issue.
Ipsen Eyes Opportunity In Rare Liver Diseases With Albireo Buy
The French firm is paying a 104% premium plus contingent value rights of an additional $10 per share to get hold of AstraZeneca spin-off Albireo and its lead asset Bylvay, which is approved for progressive familial intrahepatic cholestasis and is showing promise in two other more lucrative indications.
Zejula, Revatio Advisory Committee Meetings Cancelled; Palovarotene Panel Postponed
Panel to review overall survival data on GSK’s Zejula for ovarian cancer ‘is no longer needed,’ US FDA says. Meeting to consider pediatric indication for Viatris’ Revatio was also cancelled though sNDA remains active. FDA to review new information on Ipsen’s palovarotene clinical trial data.